TNDM vs. AXNX, IRTC, PRCT, NARI, ICUI, NVCR, IART, INSP, LMAT, and HAE
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Axonics (AXNX), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Inari Medical (NARI), ICU Medical (ICUI), NovoCure (NVCR), Integra LifeSciences (IART), Inspire Medical Systems (INSP), LeMaitre Vascular (LMAT), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Tandem Diabetes Care (NASDAQ:TNDM) and Axonics (NASDAQ:AXNX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Axonics has a net margin of -4.12% compared to Tandem Diabetes Care's net margin of -18.37%. Axonics' return on equity of -2.58% beat Tandem Diabetes Care's return on equity.
Tandem Diabetes Care received 397 more outperform votes than Axonics when rated by MarketBeat users. However, 66.92% of users gave Axonics an outperform vote while only 61.13% of users gave Tandem Diabetes Care an outperform vote.
Tandem Diabetes Care has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Axonics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
99.5% of Axonics shares are held by institutional investors. 2.2% of Tandem Diabetes Care shares are held by insiders. Comparatively, 1.9% of Axonics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Axonics has lower revenue, but higher earnings than Tandem Diabetes Care. Axonics is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care presently has a consensus price target of $49.73, indicating a potential downside of 6.00%. Axonics has a consensus price target of $70.30, indicating a potential upside of 4.72%. Given Axonics' higher probable upside, analysts plainly believe Axonics is more favorable than Tandem Diabetes Care.
In the previous week, Tandem Diabetes Care had 13 more articles in the media than Axonics. MarketBeat recorded 20 mentions for Tandem Diabetes Care and 7 mentions for Axonics. Tandem Diabetes Care's average media sentiment score of 1.42 beat Axonics' score of 1.14 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Summary
Tandem Diabetes Care and Axonics tied by winning 9 of the 18 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
